Article ID Journal Published Year Pages File Type
4281196 The American Journal of Surgery 2007 4 Pages PDF
Abstract

Pancreatic cancer is a nearly lethal disease. Patients have such a poor prognosis because there are no early symptoms. Upon presentation, most patients already have regional and systemic spread of the disease. With cure rates below 3%, long-term survival is difficult to measure. Thus, the assessment of clinical benefit has been based not only on observed 5-year survival but more frequently on actuarial, median, and disease-free survival. Surgery remains the only hope for cure, but median survival remains low despite improvements in peri- and postoperative treatment of complications and sharp decreases in perioperative morbidity and mortality. The addition of adjuvant chemo- and radiotherapy has provided a survival advantage of 6 to 10 months (increasing median survival to 20 months). However, the long-term benefit, if any, is still to be determined. Neoadjuvant therapies are also undergoing evaluation, but their role has not yet been established. True long-term survival may ultimately depend on the development of screening tools that will allow early detection (before regional and systemic spread) of this lethal disease.

Related Topics
Health Sciences Medicine and Dentistry Surgery
Authors
, ,